GLP-RT

GLP-RT Retatrutide is a synthetic peptide which is used in Type 2 Diabetes Mellitus and Weight management. It is triple agonist targeting GLP-1 receptor, pharmaceutical-grade preparation containing Retatrutide, delivered via subcutaneous injection using a prefilled, multi-dose vials. It may work as triple agonist receptor GIP/ GLP-1 and Glucagon receptor agonist that boosts insulin, reduces appetite, may allow gastric emptying, and increase energy burn.

 

Key Features

About
Drug Class	Anti-obesity agent
Subclass	Incretin mimetic
Active ingredient	Retatrutide

GLP-RT
Composition	Active ingredients Retatrutide Inactive ingredients: Water for injection Disodium hydrogen phosphate Propylene glycol Mannitol Sodium chloride
Packaging Type	Multi-dose Prefilled vial injector
Pack Size	1 vial
Dosage	10 mg and 20 mg
Active ingredients	Retatrutide
Shelf Life	Two years refrigerated for unopened vials.
Usages	Chronic weight management, Type-2 Diabetes

How does GLP-RT work?

Retatrutide is a single peptide formulated to activate 3 metabolic hormone receptors at once:

• GLP-1 receptor agonism: This may slow gastric emptying, increases satiety signals to the brain, enhances glucose-dependent insulin secretion
• GIP receptor agonism: This enhances insulin secretion and may improve fat metabolism in preclinical models
• Glucagon receptor agonism: This may increase energy expenditure and hepatic fat oxidation in research settings

Retatrutide works by mimicking 3 gut/ liver hormones to increase insulin, reduce appetite, slow digestion, and raise energy burn. This triple mechanism may produce the highest weight loss.

Effect of GLP-RT

• Appetite, strong suppression from GLP-1 and GIP action in hypothalamus and hindbrain.
• Glucose control, GLP-1 and GIP improve insulin, suppress glucagon this may lower HbA1c.
• Weight loss i.e., GLP-1 and GIP cut the intake and glucagon boosts calorie burn.
• Glucagon receptor activity may reduce liver fat and NAFLD markers more than GLP-1 singly.
• This may slow stomach emptying, i.e., smaller post-meal glucose spikes and longer satiety. 

Research Application

GLP-RT (Retatrutide) can be used in It can be used:

• Type-2 Diabetes.
• It can be used in managing weight.

Research Dosage

GLP-RT are research chemicals and is only for research purpose.

• Starting can be 1-2mg once weekly, with gradual increases every 4 weeks up to 12mg once weekly, titration is done to reduce GI side effects like nausea and vomiting.
• Do not self-titrate. Rapid dose escalation increases risk of GI side effects and pancreatitis.

Strength

• GLP-RT 10 mg
• GLP-RT 20 mg 

How to use GLP-RT?

• Let the vials reach room temperature 15-30 minutes.
• Prior check the solution, i.e., it should be always colourless with no particles.
• Clean the skin, alcohol swab let dry.
• Inject full dose, hold 5-10 sec.
• Do not reuse the needle.

Side effects and Interactions

Constipation, abdominal pain, decreased appetite, nausea, diarrhea, vomiting, heartburn, flatulence, redness, itching, dizziness can be the side effects of GLP-RT. It may interact adversely with other oral medications resulting in slowing gastric emptying this can delay absorption of other oral drugs. It also interacts with insulin/Sulfonylureas the concomitant use increases hypoglycaemia risk. Warfarin monitoring is need as it may affects the absorption. Alcohol may lead to increase the risk of other side effects.

Pharmacokinetics

• It may reach the peak plasma concentration Tmax at just 24-72 hours post Sub injection.
• Proteolytic degradation occurs to form small peptides and amino acids, similar to other GLP-1 peptides. This is followed by metabolism.
• Excretion, via kidney.

Product Specification

Specification
Peptide class	Synthetic triple incretin receptor agonist
Molecular structure	39 AA synthetic Peptide based on GIP sequence with GLP-1 and glucagon activity.
Purity (HPLC)	≥ 99%
Appearance	White to off-white fluffy lyophilized powder
Reconstitution	Use sterile water or bacteriostatic water
Solubility	Soluble in water greater than or equal to 1 mg/ml. Also soluble in DMSO for lab use.
Storage (lyophilized)	−20°C, protected from light and moisture
Storage (reconstituted)	2–8°C, use within 28 days

Precautions

• Pregnant, lactating or planning pregnancy should not opt for GLP-RT.
• Personal/family history of medullary thyroid carcinoma or MEN2. Prior history of pancreatitis, gallbladder disease, or severe GI disease, Type 1 diabetes or diabetic ketoacidosis history should avoid GLP-RT.
• Severe renal impairment dehydration risk. 

Conclusion

GLP-RT Retatrutide is a synthetic peptide which is used in Type 2 Diabetes Mellitus and Weight management. It is triple agonist targeting GLP-1 receptor, pharmaceutical-grade preparation containing Retatrutide, delivered via subcutaneous injection using a prefilled, multi-dose vials device. It acts as a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors. GIP/ GLP-1 and Glucagon receptor agonist that boosts insulin, reduces appetite, may allow gastric emptying, and increase energy burn. It may show some side effects like constipation, abdominal pain, decreased appetite, nausea, diarrhea, vomiting, heartburn, flatulence, redness, itching, dizziness. This is only for Research purpose it is not for human consumption, veterinary use or therapeutic application or any diagnostic purpose.

Related Research Peptides

You may also explore Tirzepatide, Semax 10 mg,  NAD+, and BPC-157/TB 500 peptides available at Zycare Peptides.

FAQs

For what purpose GLP-RT is used?

GLP-RT is used in Metabolic applications like weight management and Type 2 Diabetes.

How to take GLP-RT?

Subcutaneous injection once a week.

What can be possible side effects of GLP-RT?

The possible side effects of GLP-RT can be vomiting, nausea, diarrhea, constipation, abdominal pain and decreased appetite.

Who should avoid taking GLP-RT?

The one with medical history of Medullary thyroid carcinoma (MTC) or MEN2, the one with hypersensitive to Retatrutide and Type 1 Diabetes should avoid taking any such medications.

Does GLP-RT affect blood sugar?

Yes, it may lower glucose even without diabetes because of GLP-1 and GIP.

GLP-RT is only for Research purpose it is not for human consumption, veterinary use or therapeutic application or any diagnostic purpose.